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Background: Clostridium perfringens is a widespread pathogen, but the precise quantification of this subdominant
gut microbe remains difficult due to its low fecal count (particularly in asymptomatic subjects) and also due to the
presence of abundant polymerase-inhibitory substances in human feces. Also, information on the intestinal carriage
of toxigenic C. perfringens strains in healthy subjects is sparse. Therefore, we developed a sensitive quantitative
real-time PCR assays for quantification of C. perfringens in human feces by targeting its α-toxin and enterotoxin
genes. To validate the assays, we finally observed the occurrence of α-toxigenic and enterotoxigenic C. perfringens
in the fecal microbiota of healthy Japanese infants and young adults.
Methods: The plc-specific qPCR assay was newly validated, while primers for 16S rRNA and cpe genes were
retrieved from literature. The assays were validated for specificity and sensitivity in pre-inoculated fecal samples, and
were finally applied to quantify C. perfringens in stool samples from apparently healthy infants (n 124) and young
adults (n 221).
Results: The qPCR assays were highly specific and sensitive, with a minimum detection limit of 103 bacterial cells/g
feces. Alpha-toxigenic C. perfringens was detected in 36 % infants and 33 % adults, with counts ranging widely (103-
107 bacterial cells/g). Intriguingly, the mean count of α-toxigenic C. perfringens was significantly higher in infants
(6.0 ± 1.5 log10 bacterial cells/g), as compared to that in adults (4.8 ± 1.2). Moreover, the prevalence of
enterotoxigenic C. perfringens was also found to be significantly higher in infants, as compared to that in adults.
The mean enterotoxigenic C. perfringens count was 5.9 ± 1.9 and 4.8 ± 0.8 log10 bacterial cells/g in infants and
adults, respectively.
Conclusions: These data indicate that some healthy infants and young adults carry α-toxigenic and enterotoxigenic
C. perfringens at significant levels, and may be predisposed to related diseases. Thus, high fecal carriage of toxigenic
C. perfringens in healthy children warrants further investigation on its potential sources and clinical significance in
these subjects. In summary, we present a novel qPCR assay for sensitive and accurate quantification of α-toxigenic
and enterotoxigenic C. perfringens in human feces, which should facilitate prospective studies of the gut microbiota.
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Clostridium perfringens is one of the most widely dis-
persed opportunistic pathogens [1] and is well known to
produce a number of toxins to cause several forms of
histotoxic and enteric diseases in humans and animals
[2]. Based on the production of four major toxins i.e.,
alpha, beta, epsilon and iota, it is categorized into five
toxin-types viz. A, B, C, D and E [3]. While it is ambigu-
ous why C. perfringens produces so many diverse toxins,
it is well known that it uses chromosomally-encoded α-
toxin (which has phospholipase C (plc) and sphingomyeli-
nase activities with hemolytic, necrotic and lethal abilities)
as a chief virulent factor and key mediator for most
of C. perfringens-associated diseases [4]. Alpha-toxin
is produced by all C. perfringens toxin-types but type
A produces higher amounts than the other types [1].
In addition, few C. perfringens strains also harbor cpe
(C. perfringens enterotoxin, a clinically important en-
terotoxin) gene which is responsible for most of the
C. perfringens food-poisoning outbreaks and diarrheal
cases [5]. Under favorable conditions, the organism
can cause gas gangrene, food-poisoning and gastro-
intestinal illnesses including antibiotic-associated diar-
rhea, sporadic diarrhea, and nosocomial diarrheal
diseases in humans [6–9]. However, in spite of their
ubiquitous environmental distribution and implication
in various food-poisoning outbreaks worldwide [10, 11],
very little information is available on the relative occur-
rence of α-toxigenic and enterotoxigenic strains of C. per-
fringens in general populations, particularly in Japan
where C. perfringens food poisoning has been ranked as
third or fourth most common food poisoning [12–14].
Generally, a high C. perfringens count (>106 cfu/g
feces) is considered as an indicator of C. perfringens
food-poisoning [15–18]. C. perfringens in fecal samples
has traditionally been detected by conventional micro-
biological culture methods, biochemical analyses, tissue
culture cytotoxicity assays, mouse bioassays or immuno-
sorbent assays [19–21], but these methods are laborious
and time-consuming. Culture of C. perfringens is not
recommended for diagnosis, mainly because of relative
ubiquity of the bacterium in human feces. Further, since
not all isolates are toxigenic, specific toxigenic strains
that coexist with a larger population of non-toxigenic
strains may be overlooked. Biochemical tests are also in-
capable of distinguishing different types of C. perfrin-
gens. As a consequence, traditional clinical diagnosis of
enteric pathogens by conventional methods lack the
competence for large-scale investigations and the ad-
equate precision and sensitivity required for low-level
sub-clinical detection. Several immunosorbent assays
have also been developed, of which some are also com-
mercially available for detection of clostridial toxins in-
cluding C. perfringens toxins [20, 22, 23]; however, theseassays are not as sensitive as traditional methods and
often produce false-negative results [24–26]. Further,
these toxin-specific immunosorbent assays may overlook
the samples of those subjects who are carrying toxigenic
bacterium but in whom the toxin is not produced [22].
Furthermore, the toxin may not be detected, for in-
stance, if it is a modified toxin or neutralized by host
factors [24]. Therefore, to avoid such discrepancies, the
potential of PCR-based methods with specific gene tar-
gets has been explored. Rapid and specific detection has
been achieved by molecular approaches based on PCR,
and it has been used as a reliable tool to detect C. per-
fringens within complex microbial backgrounds such as
complex food products and fecal samples [27–32]. How-
ever, since complex samples such as human feces con-
tain numerous polymerase-inhibitory substances that
affect the sensitivity of PCR reactions [33, 34], majority
of the available methods require pure cultures or pre-
incubation steps in order to enumerate lower counts
(< 105 cfu/g) of toxigenic strains of C. perfringens,
particularly in the feces of asymptomatic subjects.
In this context, we developed a rapid and sensitive
qPCR assay to detect and quantify C. perfringens directly
in human fecal samples by using a novel primer pair tar-
geting the chromosomally-located plc (α-toxin) gene.
The assay was coupled with a commercially available
PCR buffer Ampdirect® Plus (Shimadzu, Japan) as a
measure to allow more efficient PCR amplification by
neutralizing the effect of inhibitory substances present in
biological samples [35]. The method was validated for
its specificity and sensitivity against various targeted
(C. perfringens) and non-targeted (non-C. perfringens
and non-clostridial species) bacterial strains, and also
for detection efficiency and reproducibility in artifi-
cially inoculated fecal samples. The final step in the
analytical validation of the assay was its application to
detect and quantify C. perfringens in fecal samples
from 345 apparently healthy Japanese subjects (infants, n
124; adults, n 221). In addition to plc gene, the samples
were also analyzed for 16S rRNA and chromosomal cpe
genes. Herein, we provide a specific, sensitive and rapid
assay for quantitative enumeration of toxigenic C. perfrin-
gens in human feces.
Methods
Primer design
The plc gene was targeted for the design of primer. The
sequence of the gene was procured from GenBank, Na-
tional Center for Biotechnology Information (NCBI)
(http://www.ncbi.nlm.nih.gov/genbank/). Multiple align-
ment of the gene sequences was performed with the
CLUSTAL_X program (http://clustalx.software.infor-
mer.com) [36] by using plc gene sequences from more
than 25 strains of C. perfringens including the three
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number: NC_008261; Gene ID: 4201274), Str. 13 (Gen-
Bank accession number: NC_003366; Gene ID: 988262)
and SM101 (GenBank accession number: NC_008262;
Gene ID: 4205371). After comparison of the sequences
in silico, target sites for C. perfringens plc-specific detec-
tion were identified and a putative oligonucleotide
primer set was designed following the primer designing
instructions from user guide catalog (http://www3.ap
pliedbiosystems.com/cms/groups/mcb_support/docume
nts/generaldocuments/cms_041053.pdf ). The primer
was subsequently checked for potential cross-reactivity
with the BLAST (Basic Local Alignment Search Tool)
database search application (http://www.ncbi.nlm.nih.gov/
BLAST), and for preliminary sensitivity and specificity by
qPCR with extracted DNA fractions from 30 Clostridium
and non-clostridia strains (Table 1 and 2). For the analysis
of cpe gene, the primer pair reported previously [37] was
used to amplify a 154 bp product from the chromosomal
cpe locus (Table 1). The details of 16S rRNA gene-specific
primer pair have previously been reported [38] (Table 1).
Bacterial strains and culture conditions
The bacterial strains used in the present investigation in-
cluded 8 C. perfringens and 22 non-C. perfringens
strains, as listed in Table 2. The strains were type strains
either from the American Type Culture Collection
(ATCC) or Japan Collection of Microorganisms (JCM).
The strain C. perfringens C052-1 was previously isolated
and characterized from human feces in the author’s la-
boratory at Yakult Central Institute. All the Clostridia
strains were routinely grown in modified Gifu anaerobic
broth (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan)
supplemented with 1 % glucose (Glu-mGAM) at 37 °C
for 24 h under anaerobic conditions. All anaerobic ma-
nipulations were performed in an anaerobic glove box
(Coy Laboratory Products Inc., Grass Lake, MI). Total
bacterial cell counts were determined by DAPI staining,
according to the method described previously [39].
Primary treatment of fecal samples
Fresh fecal specimens were collected from five healthy
adult male subjects for spiking tests, and from 124Table 1 C. perfringens targeted primers used in this study
Target Standard strain Primer Sequence (5' - 3')




cpe gene C. perfringens GAP11 GGTTCATTAATTGAA
GAP12 AACGCCAATCATATA
16S rRNA gene C. perfringens
ATCC 13124T
s-Clper-F GGGGGTTTCAACAC
ClPER-R GCAAGGGATGTCAAinfants and 221 young adults for analytical validation of
the qPCR assays (details of the subjects are provided in
subsequent sections). Immediately after defecation, a
spoonful of feces (0.5 to 1.0 g) was collected into a fecal
collection tube (Sarstedt AG & Co., Numbrecht,
Germany), and the tubes were stored at −80 °C until use
for the pretreatment for qPCR. Primary treatment of
feces for total DNA extraction was done as follows. Each
fecal sample was weighed, suspended in 9 volumes of
sterile PBS (−) to make 10-fold (v/w) dilution, and was
washed twice with PBS (−) by centrifugation at 12,000 ×
g at 4 °C for 5 min. About equal volume of glass beads
(2.5 mm, diameter), as that of fecal sample, were added
to the diluted samples, and the mixture was subjected to
vigorous vortex to make a uniform fecal homogenate
which was then divided into 200 μl aliquots and stored
at −80 °C until DNA extraction.
DNA extraction
DNA extraction was performed according to the method
previously described [40], with minor modifications.
Briefly, the thawed sample (200 μl aliquots of pure cul-
tures or primary treated fecal samples) was mixed with
250 μl of extraction buffer (100 mM Tris–HCl, 40 mM
EDTA; pH 9.0), 50 μl of 10 % sodium dodecyl sulfate,
300 mg of glass beads (diameter, 0.1 mm), and 500 μl of
Tris-EDTA-saturated phenol, and the mixture was sub-
jected to vigorous vortexing for 15 min using a Shake-
Master Auto BMS-A15 (Bio Medical Science Inc.,
Tokyo, Japan). After phenol–chloroform purification
and isopropanol precipitation of the sample, the nucleic
acid fraction was suspended in 0.1 ml of TE (pH 8.0).
Real-time qPCR assay
The specific primer sets for 16S rRNA, plc and cpe gene
(as described in Table 1) were used. For qPCR without
Ampdirect® plus (Shimadzu, Japan), each reaction mix-
ture (20 μl) was composed of 1 × PCR buffer (TaKaRa
Bio Inc., Shiga, Japan), each dNTP at a concentration of
200 μM, MgCl2 solution at a concentration of 2.5 mM, a
1:75,000 dilution of SYBR green I (BioWhittaker Mo-
lecular Applications, Rockland, ME), Takara TaqTM
(TaKaRa Bio Inc., Shiga, Japan) at a concentration ofProduct size (bp) Annealing temp (°C) Reference
GACA
TGCTAGCA 219 60 This study
ACTGGTG 154 55 [37]
AATTACAGC
CTCC 170 60 [38, 74]
GTGT
Table 2 Results of specificity tests using plc- and cpe-targeted primer sets
Taxon Strain Reactions with the following primer sets
Cper-plc508-F/R GAP11/12
(plc-target) (cpe-target)
Clostridium perfringens ATCC 13124T + –
Clostridium perfringens ATCC 9856 + –
Clostridium perfringens ATCC 3624 + –
Clostridium perfringens ATCC 3626 + –
Clostridium perfringens ATCC 12917 + +
Clostridium perfringens ATCC 14809 + +
Clostridium perfringens ATCC 27324 + –
Clostridium perfringens C052-1 + +
Clostridium ramosum JCM 1298T – –
Clostridium innocuum DSM 1286T – –
Clostridium cocleatum JCM 1397T – –
Clostridium symbiosum JCM 1297T – –
Clostridium ghonii JCM 1400T – –
Clostridium aminovalericum JCM 11016T – –
Clostridium indolis JCM 1380T – –
Clostridium paraputrificum JCM 1293T – –
Clostridium butylicum JCM 1391T – –
Clostridium difficile DSM 1296T – –
Clostridium sordellii JCM 3814T – –
Clostridium glycolicum JCM 1401T – –
Clostridium lituseburense JCM 1404T – –
Clostridium bifermentans JCM 1386T – –
Blautia producta JCM 1471T – –
Faecalibacterium prausnitzii ATCC 27768T – –
Bacteroides vulgatus ATCC 8482T – –
Collinsella aerofaciens DSM 3979T – –
Prevotella melaninogenica ATCC 25845T – –
Bifidobacterium longum ATCC 15707T – –
Clostridium innocuum DSM 1286T – –
Fusobacterium russii ATCC 25533T – –
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CA) at a concentration of 5.5 ng/μl, and 5 μl template
DNA. Each primer set was added at a final concentra-
tion of 0.2 μM. For qPCR with Ampdirect® plus (Amp-
qPCR), each reaction mixture (20 μl) was composed of
1 × Ampdirect® plus buffer, a 1:75,000 dilution of SYBR
green I, Takara TaqTM at a concentration of 0.02 units/
μl, TaqStart antibody at a concentration of 5.5 ng/μl, and
5 μl template DNA. Each primer set was added at a final
concentration of 0.2 μM. The amplification program
consisted of one cycle at 95 °C for 5 min, followed by
50 cycles at 94 °C for 20 s, 55/60 °C for 20 s, and 72 °C
for 50 s. The fluorescent products were detected at thelast step of each cycle. For determination of specificity of
the amplifications, a melting curve analysis was per-
formed in concurrence with each PCR runs by slow
heating at temperatures from 60 to 95 °C, with fluores-
cence obtained at 0.2 °C/s. qPCR amplification and de-
tection were performed in 96-well optical plates (Cat.
No. 3754; Corning Inc. Life Sciences, Japan) with an ABI
PRISM 7500 sequence detection system (version: 1.4.0;
Applied Biosystems, Foster City, CA). The plates were
sealed with optical-quality adhesive films (Cat. No. 547-
KTS-HC-P; Watson Bio-Lab Co., Ltd., Japan). The
MIQE (Minimum Information for the publication of
real-time Quantitative PCR Experiments) guidelines [41]
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signs and results.
Determination of primer specificity
The specificity of the newly-designed plc primer set and
the reported cpe primer set was tested on several target
and non-target reference strains, as listed in Table 2.
Total DNA fractions extracted from the bacterial cells of
each strain at a dose corresponding to 105 cells were
assessed for qPCR by using each primer set. Using the
standard curve from C. perfringens ATCC 13124T or C.
perfringens ATCC 12917 obtained as described above,
the amplified signal was judged to be positive when it
was more than that of 104 standard cells and negative
when it was less than that of 10−1 standard cells. The
amplified signal was defined as negative when the corre-
sponding melting curve had a peak different from that
of the standard strain. The specificity of 16S rRNA gene-
specific primer has previously been reported by using
Reverse Transcription-qPCR [38].
Determination of qPCR sensitivity
C. perfringens ATCC 13124T or C. perfringens ATCC
12917 was cultivated in Glu-mGAM broth. Bacterial
counts were determined microscopically by DAPI stain-
ing and DNA was extracted from culture samples in the
early stationary phase (24 h). Serial DNA dilutions corre-
sponding to bacterial (DAPI) counts ranging from 100 to
105 cells were assessed by Amp-qPCR assays, and the
standard curves were established. The range of DNA
concentrations at which there was linearity with the Cq
value was confirmed (R2 > 0.99).
Determination of bacterial counts by qPCR
For identification of the target bacterial population in
the fecal samples, 1/20, 1/200, 1/2,000 portion of the
DNA extracts and 1/2,000, 1/20,000, 1/200,000 portion
of the DNA extracts were subjected to Amp-qPCR and
qPCR, respectively, and the Cq values in the linear range
of the assay (100 to 105 cells) were applied to the analyt-
ical curve generated in the same experiment to obtain
the corresponding bacterial count in each nucleic acid
sample, which was converted to the count per g of feces.
Multiple NTCs were included with every assay. The Cq
values and the corresponding copy numbers for stan-
dards were included in the standard curve construction
when the Cq values of standard were smaller than those
of NTCs by 2 or more, and the LOD was defined as the
smallest bacterial number in each standard curve.
Quantification of C. perfringens spiked in human feces by
qPCR
Fresh fecal samples were collected from five healthy
adult males (ages, 28, 37, 41, 42, and 48 years) whosesamples had previously been verified by previously estab-
lished 16S rRNA gene-specific assay to be Amp-qPCR-
negative (< 103 cells/g feces) for C. perfringens [38]. The
samples were subjected to the primary treatment as de-
scribed above. It may be noted that for spiking tests, the
samples were first suspended in 4 volumes of sterilized
PBS (−) to make a 5-fold (v/w) dilution and were then
mixed with an equal amount of bacterial suspension to
obtain a 10-fold (v/w) diluted fecal suspension. An over-
night grown active culture of C. perfringens ATCC
13124T or C. perfringens ATCC 12917 was counted by
DAPI staining and serially diluted in sterilized PBS (−)
to make a series of concentrations from 2 × 107 to 2 ×
102 cells/ml, and 500 μl of these bacterial dilutions was
spiked into corresponding 500 μl of fecal homogenates
to make final concentrations ranging from 1 × 108 to 1 ×
103 cells/g of feces. DNA fractions were extracted from
200 μl of each spiked sample and were assessed by qPCR
and Amp-qPCR assays, as described above. The Cq
values obtained by the three primers were applied to the
standard curve generated with serial dilution series of C.
perfringens ATCC 13124T (16S rRNA gene and plc) or
C. perfringens ATCC 12917 (cpe) DNA corresponding to
100 to 105 cells per reaction to determine the qPCR
counts. A melting curve analysis was performed after
amplification to distinguish the target from the non-tar-
geted PCR products. For determination of the number
of bacteria in fecal samples, three serial dilutions of each
extracted DNA sample (5 μl) were used for qPCR, and
the Cq values in the linear range of the assay were ap-
plied to the standard curve generated in the same ex-
periment to obtain the corresponding number of
bacteria in each nucleic acid sample and then converted
to the number of bacteria per gram of feces.
Detection of C. perfringens in clinical samples
The newly-developed plc-specific Amp-qPCR assay was
used to quantify C. perfringens in 345 fecal samples from
apparently healthy infants (n 124; M 70; F 54; age: 167 ±
3.3 days; age range: 161–178 days) and young adults (n
221; M 153, F 68; age: 18.8 ± 0.9 years; age range: 18–22
years). The infants’ samples were obtained from Gono-
hashi Obstetrics and Gynecology Hospital, Koto-ku,
Tokyo; and the adults’ samples were from students en-
rolled at Juntendo University Graduate School of Sports
Medicine, Tokyo. Informed written consent was ob-
tained from all the subjects or their legal representatives.
The study designs of infant and adult subjects were
approved by the ethical committees of Yakult Central In-
stitute and Juntendo University Graduate School of
Medicine, respectively. Immediately after defecation,
samples were collected as per the method described
above. The infant samples were kept at 4 °C in a cooling
box with refrigerants and sent immediately to Yakult
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the primary treatment. The adults’ samples were stored
at −80 °C at the site of collection, and were transported
in a frozen state to the Yakult Central Institute where
these were stored at −80 °C until use for the primary
treatment. The samples were subjected to the primary
treatment and nucleic acid extraction, as described
above. DNA samples were finally subjected to the
newly-developed Amp-qPCR assay by using plc-specific
primer pair, and were also analyzed simultaneously by
using a previously validated 16S rRNA gene-specific pri-
mer pair for comparison purposes and also by cpe-spe-
cific primer pair for the analysis of enterotoxigenic
strains (Table 1) by Amp-qPCR.
Statistical analyses
Results of log-transformed bacterial count (log10 cells/g
feces) are expressed as mean ± standard deviation. The
program R (http://www.r-project.org) was used for stat-
istical analyses. Mann–Whitney U test and Fisher’s exact
probability test were used to calculate the mean differ-
ences in the fecal counts and the detection rates (preva-
lence), respectively. P < 0.05 was considered statistically
significant.
Results
Specificity of the primer sets
The specificity of plc- and cpe-targeted primers was
tested in vitro by using DNA fractions extracted from
several target and non-target bacterial strains corre-
sponding to 105 bacterial cells. Data providing the speci-
ficity of the designated primer sets is presented in
Table 1. The qPCR results showed high specificity of the
plc primer set for the detection of C. perfringens at the
species level. There was no amplification with any of the
DNA samples extracted from non-target microorgan-
isms, thereby authenticating the specificity of the primer
pair designed in silico. In case of cpe-targeted primer,
the assay yielded positive reaction only with three strains
i.e. ATCC 12917, ATCC 14809 and C052-1 that are
known to harbor the functional chromosomal cpe gene
(Table 1). C. perfringens ATCC 27324 also carry cpe gene
on plasmid, but this gene is non-functional due to some
specific mutation [42]. Notably, the cpe-specific primer
(GAP 11/12) did not react with this strain (Table 1),
verifying that this primer targets the conserved chromo-
somal sequence and hence detects only the functional
cpe gene.
Determination of Amp-qPCR sensitivity
The sensitivity of three Amp-qPCR (qPCR using Amp-
direct® Plus buffer) assays was tested with serial dilutions
of DNA samples extracted from respective pure cultures
of C. perfringens strains. When the Cq values wereplotted against the log10 values of the initial number of
C. perfringens cells in the qPCR to generate a standard
curve, a standard linearity of regression curves was ob-
served (Fig. 1). The counts of different C. perfringens
strains in the pure culture obtained by DAPI staining (x
axis) showed good correlation with the corresponding
Cq values obtained by the respective Amp-qPCR assay
(y axis) (Fig. 1; R2 > 0.99). All raw data i.e., Cq of the
NTCs and LOD, analytical curve and PCR efficiency are
provided in Additional file 1: Table S1 in Supplementary
Material.
Quantitative detection of C. perfringens spiked in fecal
samples
Cell counts from the 24 h old cultures were determined
by DAPI staining using fluorescent microscopy, and ser-
ial dilutions of respective cultures were spiked separately
into the fecal samples from five healthy volunteers who
had been confirmed in advance by previously established
16S rRNA gene-specific assay to be Amp-qPCR-negative
for C. perfringens (< 103 bacterial cells/g feces) in their
feces [38]. The C. perfringens counts obtained by qPCR
as well as Amp-qPCR assays were well correlated with
the expected values (R2 > 0.98; Fig. 2). The qPCR and
Amp-qPCR yielded comparable slopes of the fitted
curves, indicating that the two reactions gave similar
amplification efficiencies. However, while the LOD of all
the three qPCR assays (without Ampdirect® Plus) was
about 105 bacterial cells/g feces, it was lowered to 103
bacterial cells/g with the use of Ampdirect® Plus PCR
buffer (Amp-qPCR), indicating that the Amp-qPCR as-
says were about 100 times more sensitive than the qPCR
assays for the quantitative detection of C. perfringens in
fecal samples. Apparently, due to its ability to neutralize
the effect of PCR inhibitors, the inclusion of Ampdirect®
Plus buffer led to the use of more amount of stool
DNA extract (maximum template amount of 1/20 in
Amp-qPCR vs. 1/2,000 in qPCR) and hence a higher
detection sensitivity. The counts of spiked C. perfrin-
gens (x axis) and the corresponding counts determined
by Amp-qPCR assay (y axis) correlated well over the
bacterial concentrations ranging from 103 to 108 bac-
terial cells/g of feces (R2 > 0.99; Fig. 2). These results in-
dicated the efficiency and validity of these Amp-qPCR
assays for the specific quantification of 16S rRNA, plc and
cpe genes of C. perfringens in human feces.
Detection of C. perfringens in stool samples
The Amp-qPCR assays were finally performed to enu-
merate the populations of C. perfringens in fecal samples
from apparently healthy infants (n 124) and adult
subjects (n 221). Table 3 shows the average counts and de-
tection rates (%) of C. perfringens in the two cohorts, as
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Fig. 1 Standard curves representing the quantitative detection of reference strains of C. perfringens by Amp-qPCR assay. C. perfringens ATCC
13124T, ATCC 9856, ATCC 3624, ATCC 3626, ATCC 12917, ATCC 14809, ATCC 27324, and CS 052–1 were cultivated separately in Glu-mGAM. DNA
fractions were extracted from the culture samples in the early stationary phase (24 h), and bacterial counts were determined microscopically with
DAPI staining. 10-fold serial dilutions of DNA corresponding to the bacterial counts ranging from 100 to 105 bacterial cells were assessed by 16S
rRNA gene-specific a, plc-specific b, and cpe-specific c Amp-qPCR assays. The Cq values obtained were plotted against the log10 number of bacterial
cells subjected to each reaction. Data are expressed as means and standard deviations of the results from 7 strains (ATCC 13124T, ATCC 9856, ATCC
3624, ATCC 3626, ATCC 12917, ATCC 14809, and ATCC 27324) in the 16S rRNA gene-specific and plc-specific primer sets, and 3 strains (ATCC 12917,
ATCC 14809, and CS 052–1) in the cpe-specific primer set
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gens was detected (>103 bacterial cells/g feces) in 36 %
(44/124) of the infants and 33 % (70/221) of the adults,
and its count ranged widely (103 to 107 bacterial cells/g
feces) among each of the cohorts. The average plc+ C.
perfringens count was significantly (p = 0.00008)
higher in infants (6.0 ± 1.5 log10 bacterial cells/g), as
compared to that in adults (4.8 ± 1.2 log10 bacterial
cells/g). The mean counts obtained by plc-specific
Amp-qPCR assay were comparable with those obtained
by 16S rRNA-targeted Amp-qPCR assay (Table 2). Ac-
cordingly, matching with the results of plc-specific assay,
the average C. perfringens count analyzed by 16S rRNA-
targeted assay was also significantly higher (p = 0.000001)
in the infant cohort (6.4 ± 1.3 log10 bacterial cells/g), as
compared to that in the adult cohort (4.8 ± 1.2 log10 bac-
terial cells/g). Although, at individual level, slight numer-
ical differences between the counts analyzed by the twoassays were observed in few samples (Additional file 2:
Table S2) which can explain the minor difference in the
detection rates analyzed by the two assays (Table 2), these
differences were always less than one log value and could
be attributed to the minor differences in the specificity
and sensitivity of two different primers towards two differ-
ent genes in different PCR reactions.
Detection of enterotoxin (cpe) gene-positive C. perfringens
The samples from the two cohorts were also analyzed by
cpe-specific Amp-qPCR assay for the quantification of
enterotoxigenic C. perfringens (Table 2). The carriage
rate of cpe-positive C. perfringens was 10 % (12/124) in
the infants which was significantly (p = 0.0004) higher as
compared to that in the adults (1 %; 3/221). The average
fecal count of cpe-positive C. perfringens in these posi-
tive samples was insignificantly (p = 0.536) higher in the
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Fig. 2 Quantitative detection of C. perfringens spiked in human feces by a 16S rRNA gene-specific, b plc-specific, and c cpe-specific qPCR assays
with or without Ampdirect® Plus buffer. Strain ATCC 13124T was used as reference for 16S rRNA gene- and plc-specific assays, and ATCC 12917
was used for cpe-specific assay
Nagpal et al. BMC Microbiology  (2015) 15:219 Page 8 of 12to that in the adults (4.8 ± 0.8 log10 bacterial cells/g feces).
As expected, all the cpe-positive samples were also found
to be positive by plc- and 16S rRNA gene-specific assays,
and in most cases, the counts analyzed by cpe-specific
assay were comparable to the counts analyzed by plc- and
16S rRNA gene-specific assays. In few cases, however, the
count of cpe-positive C. perfringens was found to be lower
than the counts analyzed by plc- or 16S rRNA-specific as-
says (Additional file 2: Table S2), which may be due to the
presence of more than one strains of C. perfringens in
these subjects.
Discussion
In order to serve as an analytical tool to investigate the
intestinal carriage and prevalence of α-toxigenic and en-
terotoxigenic C. perfringens, we developed a quantitative
real-time PCR assay for rapid (within 4–5 h) and sensi-
tive detection of this subdominant but important gutTable 3 Quantitative detection of C. perfringens in stool samples from
16S rRNA, plc and cpe genes
Target Infant aged 6 months
(n = 124)
Bacterial count (log10 bacterial cells/g feces)
a Detection ra
16S rRNA gene 6.4 ± 1.3 35
plc 6.0 ± 1.5 36
cpe 5.9 ± 1.9 10
aData are expressed as the means and standard deviations
bp < 0.05 (vs. Infant aged 6 months), Mann–Whitney U test
cp < 0.05 (vs. Infant aged 6 months), Fisher’s exact probability testinhabitant in human feces. The assay had high analytical
specificity as well as sensitivity and should become an
efficient, rapid and sensitive alternate method to conven-
tional methods for the detection and quantification of C.
perfringens directly from pure cultures, feces and other
complex samples. Data on linear range as well as ampli-
fication efficiency is important in order to authenticate
the precision of qPCR for quantitative enumerations.
With a quantitative detection limit of 103 bacterial cells/g
feces, a linear range of six to seven orders of magnitude
and an acceptable reaction efficiency, our Amp-qPCR
assays demonstrated an accurate quantification of C.
perfringens from DNA extracted from pure culture or
spiked fecal homogenates (Figs. 1, 2; Additional file 1:
Table S1). We have already reported in our previous
study of C. difficile that our in-house validated nu-
cleic acid extraction method could extract RNA from
the whole clostridial cells, i.e., in both the states,healthy infants and young adults by Amp-qPCR assays targeting
Young adult
(n = 221)
te (%) Bacterial count (log10 bacterial cells/g feces)
a Detection rate (%)
4.8 ± 1.2b 31
4.8 ± 1.2b 33
4.8 ± 0.8 1c
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used DNA material in the present study, we followed
same steps for the mechanical disruption of cells and
for purification and precipitation of the nucleic acid ma-
terial. Thus, our assay could detect whole bacterial cells of
C. perfringens in feces and should be suitable for bacterial
quantification irrespective of the bacterial growth phase.
Overall, the assays developed in this study demonstrates
threefold advantage: (a) high detection sensitivity of up to
103 bacterial cells/g feces (which is significant for the de-
tection of a subdominant gut microbe), (b) targeting
chromosomal toxin gene (which is considerably important
in context of a potential opportunistic pathogen), and (c)
extraction of nucleic acids directly from feces (which
makes the assay comparatively rapid). These assays were
also used to quantify C. perfringens in samples from 124
infants and 221 adult subjects. The counts of C. perfrin-
gens in many subjects were found to be in a low range
(i.e., 103-104 bacterial cells/g feces), signifying the import-
ance of lower detection limit of 103 bacterial cells/g feces
of our assays for the investigation of fecal carriage of
toxigenic C. perfringens, particularly in asymptomatic
subjects. To our knowledge, this is the first report (a)
to validate a culture-independent qPCR assay to quan-
tify α-toxigenic and enterotoxigenic C. perfringens in
human feces with an analytical sensitivity of 103 bacter-
ial cells/g feces, and (b) to report the intestinal carriage
of these toxigenic C. perfringens strains in healthy Japanese
infants and adults.
The fecal carriage of C. perfringens has earlier been
studied (mainly in context to food-borne outbreaks), but
the information about the toxigenic strains in asymp-
tomatic subjects is limited [44–47]. It has generally been
observed that healthy people carry less than 105 C. per-
fringens cfu/g feces while patients may carry 106 or more
cfu/g [44–47]. According to our data, C. perfringens may
be present as commensal in the order of 106-108 bacterial
cells/g feces even among healthy subjects. We detected a
plc+ C. perfringens count of more than 106 bacterial cells/g
in 21.7 % infants and 7.2 % adult subjects. This finding of
higher carriage of C. perfringens, as compared to the pre-
vious studies, may be attributed to different study popula-
tions and/ or to the differences in detection sensitivities of
different methods used. We targeted the α-toxin gene to
make the assay specific for all the toxigenic C. perfringens
strains (particularly in human feces), since α-toxin is
produced by almost all the strains of C. perfringens and
has been implicated in numerous gastrointestinal ill-
nesses [4, 17, 48]. The counts analyzed by plc- and 16S
rRNA gene-specific assays were comparable (Table 2),
indicating that all the C. perfringens strains detected in
this study harbored the α-toxin gene. This finding is
consistent with those of prior studies [11, 17, 18, 30, 49].
Enterotoxigenic C. perfringens is responsible for nearly70 % of C. perfringens food-poisoning outbreaks and
20 % of all non-food-borne gastrointestinal diseases
[17, 50–53]. However, its ecology still remains under-
explored, because of the widespread environmental
distribution of C. perfringens, a very low ratio of cpe+
strains, and inability to quantify low count by major-
ity of conventional methods (< 105 bacterial cells/g)
of toxigenic strains [5]. In this context, our sensitive
culture-independent assays could be particularly im-
portant in clinical diagnosis or epidemiological inves-
tigation. Since cpe+ strains are also implicated in
antibiotic-associated diarrhea, our assay should also
find application in the analysis of such cases.
In our study, the average plc+ C. perfringens count in
infant cohort was found to be significantly higher than
that in adult subjects (Table 2). Furthermore, the preva-
lence of cpe+ C. perfringens was also significantly higher
than that in adult subjects (Table 2). Generally, about
1–5 % of C. perfringens isolates produce enterotoxin
[17, 52, 54, 55], however, in our study, the proportion
of cpe-positive subjects out of the C. perfringens-posi-
tive ones was 27 % in infants, which was significantly
(p = 0.001) higher as compared to that in adult subjects
(4 %). This finding of higher fecal carriage of cpe+ C. per-
fringens, particularly in infants, as compared to previous
studies, may again be due to the differences in detection
sensitivities of different methods used and/ or different
study populations, since previous studies were mainly
based on C. perfringens pure cultures or isolates from
foods products and adult subjects. Nonetheless, the
information on the occurrence of high population
levels of toxigenic C. perfringens in infants’ gut is particu-
larly relevant given the importance of such opportunistic
pathogens in hosts with immature or compromised im-
mune system [56–58]. It is well known that C. perfringens
can colonize the infant gut in early postnatal period
[59, 60], however it remains to be identified if the
source of toxigenic C. perfringens strains in infants is
from mother, hospital, foods or from surrounding en-
vironment, people, pets etc. Although C. perfringens
enterotoxin occasionally causes diarrhea, most infants re-
main healthy and hence may be considered as asymptom-
atic carrier of toxic pathogen [52]. Nevertheless, further
investigations are needed to elucidate why and how the
prevalence of this pathogen diminishes as these infants
grow up. It might be correlated to the maturation of the
gastrointestinal microbial ecosystem and the associated
immune system from infancy to adulthood [60–65], given
that C. perfringens has been found to be more abundant
in neonates and elderly than in adults [28, 66, 67].
We noticed that the counts of cpe+ C. perfringens var-
ied widely from 103 to 108 cells/g feces; and in most
cases, the counts analyzed by cpe-, plc- or 16S rRNA-
specific assays were comparable. Given the usefulness of
Nagpal et al. BMC Microbiology  (2015) 15:219 Page 10 of 12fecal counts of cpe+ C. perfringens, particularly the
counts of > 105 or > 106 cfu/g, in the etiology of associ-
ated diseases [68], our findings of higher counts of cpe+
C. perfringens in some healthy subjects may be an inter-
esting target for future studies. Further, the differences
in the counts analyzed by plc- and cpe-specific assays in
some samples indicate that the intestinal carriage of C.
perfringens may be diverse and that some healthy sub-
jects may also act as potential reservoir of more than
one C. perfringens strains. Such existence of cpe+ C. per-
fringens has earlier been reported [17, 52, 53]; however,
the significance of such human reservoirs in context to
the disease/ risk transmission remains to be compre-
hended. While it remains uncertain whether toxigenic C.
perfringens strains are primary pathogens or secondary
intruders of injured intestinal mucosae, from our data of
healthy subjects, it appears implausible that these strains
are primary gastrointestinal pathogens. However, it can-
not be ruled out that some healthy subjects may serve as
a reservoir for plc+ and cpe+ C. perfringens and hence
may be more prone to developing C. perfringens-associ-
ated diseases, particularly in case of impaired intestinal
mucosa and immunity or dysbiosis.
Several assays have earlier been developed for the detec-
tion of C. perfringens; however, most of these were mainly
targeted for contaminated food products [13, 69, 70]. For
example, the real-time PCR method developed by Fukush-
ima et al. [69] could detect 101 to 102 cfu/g of food-borne
pathogens in contaminated samples, but the PCR assay
was preceded by a combination of filtration and low- and
high-speed centrifugation protocols for the separation and
concentration of bacteria from contaminated food sam-
ples such as chicken, pork, beef etc. and may not be com-
petently applicable to human feces due to complex
background microbiota, inhibitory substances and differ-
ent matrixes. The assay developed by Kaneko et al. [13]
could detect >103 cfu/g of cpe-positive C. perfringens in
meat samples, but it required enrichment culture speci-
mens of spiked samples. dela Cruz et al. [29] developed a
rapid real-time fluorescence resonance energy transfer
PCR targeting plc and cpe genes of C. perfringens. How-
ever, the assay could detect about 20 copies of target se-
quence per PCR, whereas our assay could detect even a
single copy per PCR using pure culture. Few studies have
also targeted bacterial detection from feces of animals
such as pigs and poultry, but the detection limit of these
assays was about 104 cfu/g feces [71, 72]. To detect C. per-
fringens in cattle feces, Gurjar et al. [73] developed a
multiplex PCR assay with a detection limit of 30 pg and
5 pg of DNA for plc and cpe genes, respectively; however,
the assay required pre-enrichment of the fecal samples to
detect such low levels. Rinttila et al. [31] developed an
array of real-time PCR methods for the analysis of 12 en-
teric pathogens including alpha-toxigenic C. perfringensfrom the human feces; however, the detection limit was
set to 104 bacterial genomic equivalents per gram of sam-
ple. In these contexts, our assay should be particularly ad-
vantageous for large-scale investigations of epidemiology
and gut microbial ecology involving human samples since
it can detect as low as 103 toxigenic C. perfringens bacter-
ial cells per gram of human feces without requiring any
culturing step.
In summary, we have provided a novel qPCR assay for
sensitive quantification of C. perfringens in human feces.
We believe that the assay will represent a valuable ana-
lytical tool to quantify this subdominant but significant
member of gut microbiota in human samples and will
help in enhancing our understanding of its prevalence or
pathogenesis. In addition, the assay should also be uti-
lized in circumstances beyond fecal samples, and expe-
dited detection should also be applicable in assessing
foods, water, blood and other biological/ environmental
samples. It is a limitation of our study that we did not
examine C. perfringens-specific toxins, antitoxins or
their bioactivities, and hence further studies on healthy
and diseased subjects should be able to elucidate the
clinical significance of high carriage of toxigenic C. per-
fringens strains in context to gastrointestinal health and
microbiota.
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